Phase 2 study of a tetravalent chimeric dengue vaccine in healthy volunteers aged 1.5 to 45 years

Phase 2, randomised, double-blind trial in dengue fever comparing Dengue tetravalent vaccine with Placebo (2 arms). Primary endpoint: Number of participants with solicited local injection site adverse events following either vaccination dose by severity.